drug · antibody

OPDIVO QVANTIG

updated 5mo ago

by $BMY BRISTOL MYERS SQUIBB CO🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

Trials studying OPDIVO QVANTIG

phase1A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)not yet recruitingn=112
phase2Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Canceractive not recruitingn=57
phase3A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)recruitingn=690
phase3Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinomarecruitingn=900
phase2Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasisrecruitingn=134
phase2A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumorsrecruitingn=416
phase3A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%recruitingn=1,000
phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)recruitingn=450

News(10)

Unlocking cell surface protein research with site-specific labeling
Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
biospace · 16d ago
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
biospace · 16d ago
A new immuno-oncology play raises $225M for a next-generation drug
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
biopharma_dive · 21d ago
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
biopharma_dive · 27d ago
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
The FDA’s primary review team found that Replimune hadn’t sufficiently addressed deficiencies that had been pointed out in the two prior rejection letters for the melanoma therapy Tudriqev.
biospace · 27d ago
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
biospace · 28d ago
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn’t ne…
biospace · 1mo ago
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
biopharma_dive · 1mo ago
BMS picks Texas for new $2.3B manufacturing campus
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
biospace · 1mo ago
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
biopharma_dive · 1mo ago

view all news mentions →

brand

OPDIVO QVANTIG

trade names

Nivolumab bms, Nivolumab component of bms-986213, Nivolumab component of opdualag, Opdivo

generic

NIVOLUMAB

MOA

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan. In the doses administered, hyaluronidase in OPDIVO QVANTIG acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

indication

1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor a

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

OPDIVO QVANTIG

updated 5mo ago

by $BMY BRISTOL MYERS SQUIBB CO🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

Trials studying OPDIVO QVANTIG

News(10)

Unlocking cell surface protein research with site-specific labeling
Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
biospace · 16d ago
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
biospace · 16d ago
A new immuno-oncology play raises $225M for a next-generation drug
Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
biopharma_dive · 21d ago
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
biopharma_dive · 27d ago
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
The FDA’s primary review team found that Replimune hadn’t sufficiently addressed deficiencies that had been pointed out in the two prior rejection letters for the melanoma therapy Tudriqev.
biospace · 27d ago
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
biospace · 28d ago
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, integrity and transparency to the agency—but experts say that doesn’t ne…
biospace · 1mo ago
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.
biopharma_dive · 1mo ago
BMS picks Texas for new $2.3B manufacturing campus
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
biospace · 1mo ago
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
biopharma_dive · 1mo ago

view all news mentions →

brand

OPDIVO QVANTIG

trade names

Nivolumab bms, Nivolumab component of bms-986213, Nivolumab component of opdualag, Opdivo

generic

NIVOLUMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

OPDIVO QVANTIG

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OPDIVO QVANTIG

News(10)

Report a data issue

comments(0)

OPDIVO QVANTIG

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OPDIVO QVANTIG

News(10)

Report a data issue

comments(0)